APO Research
Talk to an analyst

APO RESEARCH · REPORT

Benign Prostatic Hyperplasia (BPH) Drugs

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Selected research

Industry Growth & Trends

Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Growth and Trends Forecast to 2032

29 December 2025100 pages

Choose your research edition.

Industry ResearchBenign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Benign Prostatic Hyperplasia (BPH) Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Benign Prostatic Hyperplasia (BPH) Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimates, and forecasts are presented in terms of sales volume (M Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Benign Prostatic Hyperplasia (BPH) Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Benign Prostatic Hyperplasia (BPH) Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Benign Prostatic Hyperplasia (BPH) Drugs Market by Company

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

Hospitals

Drugstores

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Benign Prostatic Hyperplasia (BPH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Alpha-Blocker Table 2. Major Company of Phosphodiesterase Type-5 Inhibitors Table 3. Major Company of Others Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2021-2026) & (US$/Unit) Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (M Units) Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2027-2032) & (US$/Unit) Table 15. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 16. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 18. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 20. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 22. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (M Units) Table 24. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends Table 26. Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers Table 27. Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges Table 28. Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2021-2026) & (M Units) Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2021-2026) Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Major Company Production Sites and Headquarters Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Company, Product Type & Application Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021-2026) & (M Units) Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2027-2032) & (M Units) Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 53. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (M Units) Table 58. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 63. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 65. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 67. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 69. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (M Units) Table 71. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 76. Eli Lilly Recent Development Table 77. GlaxoSmithKline Company Information Table 78. GlaxoSmithKline Business Overview Table 79. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 81. GlaxoSmithKline Recent Development Table 82. Astellas Pharma Company Information Table 83. Astellas Pharma Business Overview Table 84. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 86. Astellas Pharma Recent Development Table 87. Sanofi Company Information Table 88. Sanofi Business Overview Table 89. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 91. Sanofi Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 96. Pfizer Recent Development Table 97. Abbott Company Information Table 98. Abbott Business Overview Table 99. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 101. Abbott Recent Development Table 102. Allergan Company Information Table 103. Allergan Business Overview Table 104. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 106. Allergan Recent Development Table 107. TEVA Company Information Table 108. TEVA Business Overview Table 109. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 111. TEVA Recent Development Table 112. Mylan Company Information Table 113. Mylan Business Overview Table 114. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 116. Mylan Recent Development Table 117. Novartis Company Information Table 118. Novartis Business Overview Table 119. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 121. Novartis Recent Development Table 122. Merck Company Information Table 123. Merck Business Overview Table 124. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 126. Merck Recent Development Table 127. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 128. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 129. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026) Table 130. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032) & (M Units) Table 131. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 132. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 134. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country (2021-2026) Table 135. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Country (2027-2032) Table 137. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 138. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 139. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026) Table 140. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032) & (M Units) Table 141. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country (2021-2026) Table 145. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 149. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026) Table 150. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032) & (M Units) Table 151. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 154. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country (2021-2026) Table 155. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Country (2027-2032) Table 157. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 158. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 159. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026) Table 160. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032) & (M Units) Table 161. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 162. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 164. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country (2021-2026) Table 165. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (M Units): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 169. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026) Table 170. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032) & (M Units) Table 171. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 174. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country (2021-2026) Table 175. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Country (2027-2032) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List Table 180. Benign Prostatic Hyperplasia (BPH) Drugs Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Image Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2021-2032) & (M Units) Figure 5. Alpha-Blocker Image Figure 6. Global Alpha-Blocker Sales YoY Growth (2021-2032) & (M Units) Figure 7. Phosphodiesterase Type-5 Inhibitors Image Figure 8. Global Phosphodiesterase Type-5 Inhibitors Sales YoY Growth (2021-2032) & (M Units) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (M Units) Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospitals Image Figure 26. Global Hospitals Sales YoY Growth (2021-2032) & (M Units) Figure 27. Drugstores Image Figure 28. Global Drugstores Sales YoY Growth (2021-2032) & (M Units) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (M Units) Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 44. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 52. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 56. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Units) Figure 60. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-Blocker
  • Phosphodiesterase Type-5 Inhibitors
  • Others
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Eli Lilly
  • GlaxoSmithKline
  • Astellas Pharma
  • Sanofi
  • Pfizer
  • Abbott
  • Allergan
  • TEVA
  • Mylan
  • Novartis
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
  6. 1.3.1 Alpha-Blocker
  7. 1.3.2 Phosphodiesterase Type-5 Inhibitors
  8. 1.3.3 Others
  9. 1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  10. 1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
  2. 2.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
  3. 2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
  4. 2.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Price (2021-2026)
  4. 3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Company, Product Type & Application
  7. 3.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Benign Prostatic Hyperplasia (BPH) Drugs Tier 1, Tier 2, and Tier 3
4 Benign Prostatic Hyperplasia (BPH) Drugs Regional Status and Outlook
  1. 4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Region
  3. 4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Benign Prostatic Hyperplasia (BPH) Drugs by Application
  1. 5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  6. 5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly
  2. 6.1.1 Eli Lilly Company Information
  3. 6.1.2 Eli Lilly Business Overview
  4. 6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  6. 6.1.5 Eli Lilly Recent Developments
  7. 6.2 GlaxoSmithKline
  8. 6.2.1 GlaxoSmithKline Company Information
  9. 6.2.2 GlaxoSmithKline Business Overview
  10. 6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  12. 6.2.5 GlaxoSmithKline Recent Developments
  13. 6.3 Astellas Pharma
  14. 6.3.1 Astellas Pharma Company Information
  15. 6.3.2 Astellas Pharma Business Overview
  16. 6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  18. 6.3.5 Astellas Pharma Recent Developments
  19. 6.4 Sanofi
  20. 6.4.1 Sanofi Company Information
  21. 6.4.2 Sanofi Business Overview
  22. 6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  24. 6.4.5 Sanofi Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Abbott
  32. 6.6.1 Abbott Company Information
  33. 6.6.2 Abbott Business Overview
  34. 6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  36. 6.6.5 Abbott Recent Developments
  37. 6.7 Allergan
  38. 6.7.1 Allergan Company Information
  39. 6.7.2 Allergan Business Overview
  40. 6.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  42. 6.7.5 Allergan Recent Developments
  43. 6.8 TEVA
  44. 6.8.1 TEVA Company Information
  45. 6.8.2 TEVA Business Overview
  46. 6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  48. 6.8.5 TEVA Recent Developments
  49. 6.9 Mylan
  50. 6.9.1 Mylan Company Information
  51. 6.9.2 Mylan Business Overview
  52. 6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  54. 6.9.5 Mylan Recent Developments
  55. 6.10 Novartis
  56. 6.10.1 Novartis Company Information
  57. 6.10.2 Novartis Business Overview
  58. 6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  60. 6.10.5 Novartis Recent Developments
  61. 6.11 Merck
  62. 6.11.1 Merck Company Information
  63. 6.11.2 Merck Business Overview
  64. 6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  66. 6.11.5 Merck Recent Developments
7 North America by Country
  1. 7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
  2. 7.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  6. 7.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
  2. 8.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  6. 8.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
  2. 10.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  6. 10.2.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
  2. 12.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
  7. 12.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
  10. 12.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst